16. Im happy to. Nkats, now just three years old, was the first new center at nih again, quite a long time and was focused in trying to identify the bottle necks from going from basic science discoveries to benefits. In collaboration with our partners in the private sector. I think initially there were some concerns that nih is becoming a drug company, that really was never the plan and is not happening now. Instead, we are identifying areas of Technology Development that no Single Company could undertake, but working with them, we can give you just one example. The effort to try to figure out when youre developing a new drug, whether its going to be safe in humans or not. Has been a real difficult one. We use animal studies, small animals, large animals. Its not that accurate. Its slow, its expensive. We probably lose drugs along the way because some mouse got a slight liver issue and it probably would have had no relevance to humans but we sort of lose the drug at that point. Wouldnt
Cancer, what we can do about it. But the other component which is a longterm ambitious to be sure effort is this cohort of a million or more americans, which we could be studying for virtually all diseases and knowing that you are a dentist i would certainly include in that such things as periodontal disease. We know the environment and genetic risk are involved in those conditions. But we really havent had a sufficiently large study with appropriate patient participation to be able to get those answers. This should be a way to go there. So thats true for diabetes, for Heart Disease, for alzheimers disease, for virtually every common condition with a million people, youre going to have enough events you should really be able to dissect, what were the biomarkers that warned this would happen what were the environmental factors that played a role. We never had that power before we aim to get it. Thats fascinating stuff, and could really advance the advancement of diseases and cure diseas
On April 26, 2023, the FDIC and the OCC each issued separate guidance on overdraft fees. Both agencies state that “authorize positive, settle negative” (APSN) overdraft fees can be.
Silicon Valley Bank, Signature Bank collapse sent shockwaves through companies that rely on bank credit commitments to fund operations. Businesses with deposits at those banks spent weekend scrambling to secure cash for payroll already earned.
The collapse of Silicon Valley Bank and Signature Bank on March 10 and 12, 2023, respectively, sent shockwaves through the venture capital, entrepreneur, technology innovation, and life.